Developer docs
API playgroundTry for free, no card

Search company profiles

Areterna

Full company profile

uuid003nihi

Namestring
Areterna
Legal namestring
Areterna LLC
Websiteurl
areterna.com
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Areterna LLC is a US-based biotechnology company founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd (founded 2018 in China), serving as the commercial arm for mRNA and oligonucleotide raw materials in the US and European markets. The company supplies a broad portfolio of reagents and consumables used in mRNA synthesis and oligonucleotide manufacturing — including cap analogs (with proprietary license-free IP including the CAP5/ENE generation), standard and modified nucleotides (50+ variants), engineered enzymes such as low-dsRNA T7 RNA polymerase, proprietary ionizable lipids (LNP007, LNP009, LNP016), IVT and capping kits, ELISA-based impurity detection kits, tool mRNAs, phosphoramidites, nucleosides, and dNTP/ddNTP lines for molecular diagnostics. Areterna also offers services spanning analytical development, LNP screening, IVT process development, custom oligo synthesis, antibody-LNP conjugation for in vivo CAR-T applications (HiSynth platform), and an end-to-end veterinary mRNA vaccine development service with BSL-3 capability priced at approximately $0.50 per dose. The business model is primarily unit-based product sales (RUO and GMP grades) supplemented by professional services and channel distribution through BIORON GmbH (Germany), Medsol (Egypt), and Bion2 (Czechia), with a co-development partnership with Biomay AG extending reach into European and North American mRNA CDMOs. Customer segments include pharma and biotech companies developing mRNA therapeutics and vaccines, mRNA CDMOs, cell therapy developers working on in vivo CAR-T, and veterinary vaccine companies.

Short descriptiontext

Areterna is a US-based subsidiary of Synthgene Biotechnology that supplies mRNA and oligonucleotide raw materials — cap analogs, nucleotides, enzymes, LNPs, and IVT kits — alongside services such as antibody-LNP conjugation and veterinary vaccine development, serving pharma, biotech, and CDMO customers globally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGaithersburg, United States
HQ citystring
Gaithersburg
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
mRNA raw materials, oligonucleotide synthesis reagents, cap analogs manufacturing, lipid nanoparticle delivery, GMP nucleotide supply
Industry4 codes
PRIMARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
NAICS code4 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Medicinal Chemicals & Botanical Products2833
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
mRNA Manufacturing Raw Materials
Social media profiles2 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1mRNA Raw Materials Sales
TypeHardware Sales
Description

Sale of cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, and IVT kits for mRNA synthesis and manufacturing. Products available in RUO and GMP grades.

areterna.com
2Oligonucleotide Raw Materials Sales
TypeHardware Sales
Description

Sale of phosphoramidites for solid-phase DNA and RNA synthesis supporting cGMP oligo manufacturing.

areterna.com
3GMP-Grade Product Sales
TypeOne Time License
Description

GMP-grade raw materials including cap analogs, NTPs, and modified NTPs for clinical trials and commercial manufacturing. Drug Master Files filed with FDA.

areterna.com
4Veterinary mRNA Vaccine Development Services
TypeProfessional Services
Description

End-to-end service for animal mRNA vaccine development including sequence design, mRNA synthesis, LNP formulation, analytical testing, and pre-clinical testing.

areterna.com
5Antibody-LNP Conjugation Services
TypeProfessional Services
Description

Conjugation and encapsulation services for antibody-LNP formulations enabling in vivo CAR-T research.

areterna.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure
Pricing details3 tiers
1Veterinary mRNA vaccine candidates
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Approximately $0.50 per dose for animal vaccine candidates including Rabies, FIPV, and PEDV vaccines. Available for out-licensing and commercialization.

areterna.com
2Cap Analogs Product Line
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Available sizes: 100μL, 1mL, 10mL, 100mL, 500mL. Current 20% discount promotion valid through December 31, 2025 for US and EU customers (code: CAP20).

areterna.com
3GMP Grade Products
ModelUnit PricingBilling cadenceMulti-year contract
Notes

Custom packaging and bulk pricing available. Regulatory documentation including CoAs, TSE/BSE statements provided.

areterna.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1HiSynth
Description

HiSynth antibody-LNP conjugation technology platform for in vivo CAR-T therapy

areterna.com
Core offering1 text field

Areterna manufactures and sells raw materials and reagents used by pharma and biotech companies to build mRNA and oligonucleotide-based medicines, including cap analogs, standard and modified nucleotides, enzymes, ionizable lipids and LNP screening products, IVT and capping kits, impurity detection kits, tool mRNAs, and a full range of phosphoramidites and nucleosides. The catalog is offered in both RUO and GMP grades, with selected cap analogs covered by Drug Master Files filed with the FDA. In parallel, Areterna delivers professional services spanning animal mRNA vaccine development, antibody-LNP conjugation for in vivo CAR-T, LNP screening, IVT process development, analytical method development, and custom oligonucleotide synthesis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CAP5 (ENE) provides superior antigenicity against VZV with stronger gE-specific IgG antibody responses and higher VZV-specific IFNγ levels compared to benchmark m7GpppAmG in mice
+3 more records
Product overview1 text field

Areterna is a biotechnology company providing mRNA and oligonucleotide raw materials, reagents, and services for therapeutic development. The product portfolio includes four major categories: (1) mRNA Raw Materials - covering cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, IVT kits, detection kits, tool mRNAs, and CAR-T related products; (2) Phosphoramidites - DNA and RNA phosphoramidite building blocks including DNA, 2'-O-TBDMS, 2'-O-Me, 2'-O-MOE, 2'-Fluoro, and 2'-O-Propargyl variants; (3) Nucleosides - modified and protected nucleosides for oligonucleotide synthesis; and (4) Molecular Diagnostics - dNTPs, dNMPs/dNDPs, and ddNTPs for PCR, sequencing, and diagnostics. The company also offers services including animal mRNA vaccine development, analytical development, LNP screening, IVT process development, and custom oligo synthesis. All products are backed by ISO9001-certified quality systems, with GMP-grade materials available for clinical trials and Drug Master Files filed with FDA.

Product and service1 record
1Cap Analogs
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-20
Description

Distribution agreement for Eastern Europe signed between Synthgene Bio, BIORON, and Bion2. Represents a major step toward global expansion, enhancing access to key resources for mRNA and oligo research and manufacturing in Eastern Europe.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-18
Description

Strategic partnership to jointly serve mRNA CDMO customers in Europe and North America. Collaboration expands Areterna's reach in Europe and strengthens Biomay's mRNA CDMO offerings with low-cost GMP raw materials from Areterna.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-29
Description

Global distribution agreement with BIORON GmbH, a premium manufacturer and distributor based in Römerberg, Germany. BIORON distributes Areterna's mRNA and oligonucleotide raw materials globally, providing custom clearance and local language support.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-02-26
Description

Global distribution agreement with Medsol Corporation, a distributor based in Cairo, Egypt. Medsol provides distribution services for Areterna's raw materials and services in the Middle East region.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ChemGenes manufactures phosphoramidites, nucleosides, and other nucleic acid synthesis building blocks for DNA, RNA, and oligonucleotide production. It directly competes with Areterna's phosphoramidite and nucleoside lines.

TypeBroad incumbent
Description

Agilent supplies phosphoramidites, reagents, and instruments for oligonucleotide synthesis and molecular diagnostics through its diagnostics and genomics group. Its phosphoramidite and dNTP lines partially overlap with Areterna's portfolio.

TypeDirect peer
Description

Jena Bioscience supplies nucleotides, modified nucleotides, cap analogs, and reagents for mRNA synthesis and oligonucleotide chemistry. Its product portfolio directly overlaps with Areterna's nucleotide, cap analog, and reagent catalog.

TypeEmerging player
Description

Bioneer manufactures nucleotides, oligo synthesis reagents, and molecular biology enzymes, with growing GMP and mRNA-related offerings. It is an emerging peer intersecting with Areterna's nucleotide, enzyme, and oligo reagent lines.

TypeBroad incumbent
Description

Cytiva (formerly part of GE Life Sciences) provides nucleic acid synthesis reagents, oligonucleotides, and bioprocessing products. Its oligo synthesis and nucleic acid chemistry lines overlap with Areterna's phosphoramidite and reagent offerings.

6Merck KGaA / Sigma-Aldrich (Life Science)
TypeBroad incumbent
Description

Merck's Life Science business supplies a deep catalog of nucleotides, modified nucleotides, enzymes, and lipids for mRNA and oligonucleotide synthesis, including GMP-grade offerings. It is a broad incumbent competitor to Areterna's reagent portfolio.

TypeDirect peer
Description

Hongene Biotech produces modified nucleotides, phosphoramidites, and nucleic acid synthesis reagents, with GMP capabilities. It is a direct competitor to Areterna across the modified nucleotide and oligo raw material portfolio.

TypeBroad incumbent
Description

Thermo Fisher operates a large life sciences tools portfolio including nucleic acid reagents, mRNA synthesis materials, GMP manufacturing services, and CDMO capabilities through Patheon. It competes broadly with Areterna across reagents and services but at far larger scale.

TypeDirect peer
Description

BioSynth manufactures nucleotides, enzyme substrates, and carbohydrate/peptide chemistry for research and diagnostic applications. Its nucleotide and reagent lines overlap with Areterna's mRNA and oligo raw material offerings.

TypeDirect peer
Description

TriLink is a leading manufacturer of mRNA capping reagents (notably the patented CleanCap cap analog), modified nucleotides, and GMP-grade mRNA raw materials for therapeutic developers. It is the closest direct competitor to Areterna's cap analog and mRNA raw material portfolio.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Areterna

mRNA Manufacturing Raw Materialsareterna.com

Areterna is a US-based subsidiary of Synthgene Biotechnology that supplies mRNA and oligonucleotide raw materials — cap analogs, nucleotides, enzymes, LNPs, and IVT kits — alongside services such as antibody-LNP conjugation and veterinary vaccine development, serving pharma, biotech, and CDMO customers globally.

What Areterna does

Areterna LLC is a US-based biotechnology company founded in 2023 as a wholly owned subsidiary of Synthgene Biotechnology Co., Ltd (founded 2018 in China), serving as the commercial arm for mRNA and oligonucleotide raw materials in the US and European markets. The company supplies a broad portfolio of reagents and consumables used in mRNA synthesis and oligonucleotide manufacturing — including cap analogs (with proprietary license-free IP including the CAP5/ENE generation), standard and modified nucleotides (50+ variants), engineered enzymes such as low-dsRNA T7 RNA polymerase, proprietary ionizable lipids (LNP007, LNP009, LNP016), IVT and capping kits, ELISA-based impurity detection kits, tool mRNAs, phosphoramidites, nucleosides, and dNTP/ddNTP lines for molecular diagnostics. Areterna also offers services spanning analytical development, LNP screening, IVT process development, custom oligo synthesis, antibody-LNP conjugation for in vivo CAR-T applications (HiSynth platform), and an end-to-end veterinary mRNA vaccine development service with BSL-3 capability priced at approximately $0.50 per dose. The business model is primarily unit-based product sales (RUO and GMP grades) supplemented by professional services and channel distribution through BIORON GmbH (Germany), Medsol (Egypt), and Bion2 (Czechia), with a co-development partnership with Biomay AG extending reach into European and North American mRNA CDMOs. Customer segments include pharma and biotech companies developing mRNA therapeutics and vaccines, mRNA CDMOs, cell therapy developers working on in vivo CAR-T, and veterinary vaccine companies.

Areterna firmographics

Firmographics
Name
Areterna
Legal name
Areterna LLC
Website
https://areterna.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
1–10 employees
Short description
Areterna is a US-based subsidiary of Synthgene Biotechnology that supplies mRNA and oligonucleotide raw materials — cap analogs, nucleotides, enzymes, LNPs, and IVT kits — alongside services such as antibody-LNP conjugation and veterinary vaccine development, serving pharma, biotech, and CDMO customers globally.
Ownership category
akta.pro rank

Areterna industry classification

Industry
Product category
mRNA Manufacturing Raw Materials
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414), In-Vitro Diagnostic Substance Manufacturing (325413), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAF
RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAGAIAI
Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes)
SECONDARYHLAAADAA
mRNA Therapeutics (vaccines, protein replacement, immuno-oncology)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAAMAL
Biomarker Assay & Reagent Development (LDT/IVD assay design, antibodies/standards/controls)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics

Keywords

  • MRNA raw materials
  • Oligonucleotide synthesis reagents
  • Cap analogs manufacturing
  • Lipid nanoparticle delivery
  • GMP nucleotide supply

Where Areterna is headquartered

Location

Headquarters

HQ city
Gaithersburg
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Areterna business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. mRNA Raw Materials Sales: Sale of cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, and IVT kits for mRNA synthesis and manufacturing. Products available in RUO and GMP grades.
  2. Oligonucleotide Raw Materials Sales: Sale of phosphoramidites for solid-phase DNA and RNA synthesis supporting cGMP oligo manufacturing.
  3. GMP-Grade Product Sales: GMP-grade raw materials including cap analogs, NTPs, and modified NTPs for clinical trials and commercial manufacturing. Drug Master Files filed with FDA.
  4. Veterinary mRNA Vaccine Development Services: End-to-end service for animal mRNA vaccine development including sequence design, mRNA synthesis, LNP formulation, analytical testing, and pre-clinical testing.
  5. Antibody-LNP Conjugation Services: Conjugation and encapsulation services for antibody-LNP formulations enabling in vivo CAR-T research.

Pricing tiers

ModelBillingPrice
Unit PricingMulti-year contractVeterinary mRNA vaccine candidates
Unit PricingPay-as-you-goCap Analogs Product Line
Unit PricingMulti-year contractGMP Grade Products

Go-to-market motion3 records

Distribution channels5 records

Marketing channels7 records

Areterna product offering

Product offering

Core offering

Areterna manufactures and sells raw materials and reagents used by pharma and biotech companies to build mRNA and oligonucleotide-based medicines, including cap analogs, standard and modified nucleotides, enzymes, ionizable lipids and LNP screening products, IVT and capping kits, impurity detection kits, tool mRNAs, and a full range of phosphoramidites and nucleosides. The catalog is offered in both RUO and GMP grades, with selected cap analogs covered by Drug Master Files filed with the FDA. In parallel, Areterna delivers professional services spanning animal mRNA vaccine development, antibody-LNP conjugation for in vivo CAR-T, LNP screening, IVT process development, analytical method development, and custom oligonucleotide synthesis.

Product overview

Areterna is a biotechnology company providing mRNA and oligonucleotide raw materials, reagents, and services for therapeutic development. The product portfolio includes four major categories: (1) mRNA Raw Materials - covering cap analogs, nucleotides, modified nucleotides, enzymes, LNP products, IVT kits, detection kits, tool mRNAs, and CAR-T related products; (2) Phosphoramidites - DNA and RNA phosphoramidite building blocks including DNA, 2'-O-TBDMS, 2'-O-Me, 2'-O-MOE, 2'-Fluoro, and 2'-O-Propargyl variants; (3) Nucleosides - modified and protected nucleosides for oligonucleotide synthesis; and (4) Molecular Diagnostics - dNTPs, dNMPs/dNDPs, and ddNTPs for PCR, sequencing, and diagnostics. The company also offers services including animal mRNA vaccine development, analytical development, LNP screening, IVT process development, and custom oligo synthesis. All products are backed by ISO9001-certified quality systems, with GMP-grade materials available for clinical trials and Drug Master Files filed with FDA.

Differentiator

Problem solved

Functional benefit

Brands

  • HiSynth: HiSynth antibody-LNP conjugation technology platform for in vivo CAR-T therapy

Products and services

  • Cap Analogs

Quantifiable outcome

  • CAP5 (ENE) provides superior antigenicity against VZV with stronger gE-specific IgG antibody responses and higher VZV-specific IFNγ levels compared to benchmark m7GpppAmG in mice
  • +3 more outcomes

Companies that use Areterna

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Areterna technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Areterna partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Bion2coreChannel Partner/ Reseller/ Distributor · 20 February 2025Distribution agreement for Eastern Europe signed between Synthgene Bio, BIORON, and Bion2. Represents a major step toward global expansion, enhancing access to key resources for mRNA and oligo research and manufacturing in Eastern Europe.
  • Biomay AGcoreStrategic or Co-development Partner · 18 September 2024Strategic partnership to jointly serve mRNA CDMO customers in Europe and North America. Collaboration expands Areterna's reach in Europe and strengthens Biomay's mRNA CDMO offerings with low-cost GMP raw materials from Areterna.
  • BIORON GmbHcoreChannel Partner/ Reseller/ Distributor · 29 February 2024Global distribution agreement with BIORON GmbH, a premium manufacturer and distributor based in Römerberg, Germany. BIORON distributes Areterna's mRNA and oligonucleotide raw materials globally, providing custom clearance and local language support.
  • Medsol CorporationcoreChannel Partner/ Reseller/ Distributor · 26 February 2024Global distribution agreement with Medsol Corporation, a distributor based in Cairo, Egypt. Medsol provides distribution services for Areterna's raw materials and services in the Middle East region.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Areterna competitors and assessment

Company assessment

Direct peers

  • ChemGenes: ChemGenes manufactures phosphoramidites, nucleosides, and other nucleic acid synthesis building blocks for DNA, RNA, and oligonucleotide production. It directly competes with Areterna's phosphoramidite and nucleoside lines.
  • Jena Bioscience: Jena Bioscience supplies nucleotides, modified nucleotides, cap analogs, and reagents for mRNA synthesis and oligonucleotide chemistry. Its product portfolio directly overlaps with Areterna's nucleotide, cap analog, and reagent catalog.
  • Hongene Biotech: Hongene Biotech produces modified nucleotides, phosphoramidites, and nucleic acid synthesis reagents, with GMP capabilities. It is a direct competitor to Areterna across the modified nucleotide and oligo raw material portfolio.
  • BioSynth: BioSynth manufactures nucleotides, enzyme substrates, and carbohydrate/peptide chemistry for research and diagnostic applications. Its nucleotide and reagent lines overlap with Areterna's mRNA and oligo raw material offerings.
  • TriLink BioTechnologies: TriLink is a leading manufacturer of mRNA capping reagents (notably the patented CleanCap cap analog), modified nucleotides, and GMP-grade mRNA raw materials for therapeutic developers. It is the closest direct competitor to Areterna's cap analog and mRNA raw material portfolio.

Broad incumbents

  • Agilent Technologies: Agilent supplies phosphoramidites, reagents, and instruments for oligonucleotide synthesis and molecular diagnostics through its diagnostics and genomics group. Its phosphoramidite and dNTP lines partially overlap with Areterna's portfolio.
  • Cytiva: Cytiva (formerly part of GE Life Sciences) provides nucleic acid synthesis reagents, oligonucleotides, and bioprocessing products. Its oligo synthesis and nucleic acid chemistry lines overlap with Areterna's phosphoramidite and reagent offerings.
  • Merck KGaA / Sigma-Aldrich (Life Science): Merck's Life Science business supplies a deep catalog of nucleotides, modified nucleotides, enzymes, and lipids for mRNA and oligonucleotide synthesis, including GMP-grade offerings. It is a broad incumbent competitor to Areterna's reagent portfolio.
  • Thermo Fisher Scientific: Thermo Fisher operates a large life sciences tools portfolio including nucleic acid reagents, mRNA synthesis materials, GMP manufacturing services, and CDMO capabilities through Patheon. It competes broadly with Areterna across reagents and services but at far larger scale.

Emerging players

  • Bioneer: Bioneer manufactures nucleotides, oligo synthesis reagents, and molecular biology enzymes, with growing GMP and mRNA-related offerings. It is an emerging peer intersecting with Areterna's nucleotide, enzyme, and oligo reagent lines.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Areterna social profiles

Digital presence

Areterna compliance and trust

Trust signal

Compliance2 records

Areterna financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Areterna leadership team

Management profile

Number of profiles

Areterna funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Areterna M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Areterna

What does Areterna do?

Areterna manufactures and sells raw materials and reagents used by pharma and biotech companies to build mRNA and oligonucleotide-based medicines, including cap analogs, standard and modified nucleotides, enzymes, ionizable lipids and LNP screening products, IVT and capping kits, impurity detection kits, tool mRNAs, and a full range of phosphoramidites and nucleosides. The catalog is offered in both RUO and GMP grades, with selected cap analogs covered by Drug Master Files filed with the FDA. In parallel, Areterna delivers professional services spanning animal mRNA vaccine development, antibody-LNP conjugation for in vivo CAR-T, LNP screening, IVT process development, analytical method development, and custom oligonucleotide synthesis.

Is Areterna a public or private company?

Areterna is a private company. It is classified as corporate owned and is currently operating.

When was Areterna founded?

Areterna was founded in 2023. It employs 1 to 10 people.

Where is Areterna based?

Areterna is headquartered in Gaithersburg, United States, in the North America region.

How does Areterna make money?

Five revenue lines are on record. mRNA Raw Materials Sales are the primary driver. The others are oligonucleotide Raw Materials Sales, GMP-Grade Product Sales, veterinary mRNA Vaccine Development Services and antibody-LNP Conjugation Services.

Who are Areterna's main competitors?

Direct peers on record are ChemGenes, Jena Bioscience, Hongene Biotech, BioSynth and TriLink BioTechnologies. Broad incumbents are Agilent Technologies, Cytiva, Merck KGaA / Sigma-Aldrich (Life Science) and Thermo Fisher Scientific. Bioneer is listed as an emerging player.

Does Areterna have an API?

No public API is recorded for Areterna.

What industry is Areterna in?

Areterna's product category is mRNA Manufacturing Raw Materials. Its primary akta.pro industry code is HLAAADAF, RNA Manufacturing & CMC (oligo synthesis, IVT, purification, formulation, QC), with a secondary code of HLAGAIAI, Reagents, Chemicals & Assay Kits (Buffers, Antibodies, ELISA, Enzymes). Its NAICS code is 3254 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals